Optimisation of the HepaRG cell line model for drug toxicity studies using two different cultivation conditions: advantages and limitations

[1]  A. Nussler,et al.  Assessment of tobacco heating system 2.4 on osteogenic differentiation of mesenchymal stem cells and primary human osteoblasts compared to conventional cigarettes , 2020, World Journal of Stem Cells.

[2]  J. Hengstler,et al.  Towards improved hepatocyte cultures: Progress and limitations. , 2020, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[3]  Mitchell R. McGill,et al.  Animal models of drug-induced liver injury. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[4]  G. Damm,et al.  Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity , 2019, International journal of molecular sciences.

[5]  A. Nussler,et al.  Nicotine and Cotinine Inhibit Catalase and Glutathione Reductase Activity Contributing to the Impaired Osteogenesis of SCP-1 Cells Exposed to Cigarette Smoke , 2018, Oxidative medicine and cellular longevity.

[6]  R. ter Horst,et al.  Establishing normal metabolism and differentiation in hepatocellular carcinoma cells by culturing in adult human serum , 2018, Scientific Reports.

[7]  S. Ohta,et al.  Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. , 2018, Biological & pharmaceutical bulletin.

[8]  Ans Punt,et al.  Non-animal approaches for toxicokinetics in risk evaluations of food chemicals. , 2017, ALTEX.

[9]  Jonathan P. Jackson,et al.  Contextualizing Hepatocyte Functionality of Cryopreserved HepaRG Cell Cultures , 2016, Drug Metabolism and Disposition.

[10]  M. Ingelman-Sundberg,et al.  A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity , 2016, Archives of Toxicology.

[11]  Lei Guo,et al.  The role of CYP 3A4 and 1A1 in amiodarone-induced hepatocellular toxicity. , 2016, Toxicology letters.

[12]  Nils Blüthgen,et al.  Gene network activity in cultivated primary hepatocytes is highly similar to diseased mammalian liver tissue , 2016, Archives of Toxicology.

[13]  Jeffrey K Aronson,et al.  Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis , 2016, Critical reviews in toxicology.

[14]  A. Urtti,et al.  Hepatic differentiation of human pluripotent stem cells on human liver progenitor HepaRG-derived acellular matrix. , 2016, Experimental Cell Research.

[15]  F. Jamali,et al.  The Pharmacokinetics of Ibuprofen in Humans and Animals , 2015 .

[16]  P. Bharatam,et al.  Drug metabolism , 2014 .

[17]  S. Hammad.  Advances in 2D and 3D in vitro systems for hepatotoxicity testing , 2013, EXCLI journal.

[18]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[19]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[20]  G. Damm,et al.  Hepatic 3D cultures but not 2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity , 2013, Archives of Toxicology.

[21]  U. Müller-Vieira,et al.  Analysis of drug metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies , 2012, Biotechnology and bioengineering.

[22]  Leming Shi,et al.  Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes , 2011, Drug Metabolism and Disposition.

[23]  Thomas Hartung,et al.  Are in vitro tests suitable for regulatory use? , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  Tommy B Andersson,et al.  Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies , 2008, Drug Metabolism and Disposition.

[25]  Valérie Fessard,et al.  Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies , 2008, Drug Metabolism and Disposition.

[26]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[27]  B. Drénou,et al.  Transdifferentiation of hepatocyte‐like cells from the human hepatoma HepaRG cell line through bipotent progenitor , 2007, Hepatology.

[28]  R. de Kanter,et al.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.

[29]  Olivier Fardel,et al.  Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  Albert P. Li,et al.  Accurate prediction of human drug toxicity: a major challenge in drug development. , 2004, Chemico-biological interactions.

[31]  Magnus Ingelman-Sundberg,et al.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. , 2004, Trends in pharmacological sciences.

[32]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  O. Fardel,et al.  Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. , 2001, Life sciences.

[34]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[35]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[36]  B. Brodie,et al.  PATHWAYS OF DRUG METABOLISM * , † , 1956, The Journal of pharmacy and pharmacology.

[37]  F. Hu,et al.  Cell Culture Models and Animal Models for HBV Study. , 2020, Advances in experimental medicine and biology.

[38]  M. T. Donato,et al.  Culture and Functional Characterization of Human Hepatoma HepG2 Cells. , 2015, Methods in molecular biology.

[39]  J. Nowak,et al.  Paracetamol: mechanism of action, applications and safety concern. , 2014, Acta poloniae pharmaceutica.

[40]  A. Müsch,et al.  Hepatocyte polarity. , 2013, Comprehensive Physiology.

[41]  Ivan Rusyn,et al.  In vitro models for liver toxicity testing. , 2013, Toxicology research.

[42]  J. Gerlach,et al.  HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. , 2011, Journal of pharmacological and toxicological methods.

[43]  S. Dooley,et al.  Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism , 2011, Archives of Toxicology.

[44]  David Durantel,et al.  The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. , 2010, Methods in molecular biology.

[45]  A. Capitano,et al.  Induction of Zone‐Like Liver Function Gradients in HepG2 Cells by Varying Culture Medium Height , 2007, Biotechnology progress.

[46]  F. Ballet,et al.  Hepatotoxicity in drug development: detection, significance and solutions. , 1997, Journal of hepatology.

[47]  M. B. Grivell,et al.  Techniques for pharmacological and toxicological studies with isolated hepatocyte suspensions. , 1992, Life sciences.